Menarini Group, Stemline Therapeutics, and MEDSIR have presented groundbreaking research on the ADELA clinical trial, which targets therapeutic resistance in advanced ER+/HER2- breast cancer. This research was shared at the…
Sirius Therapeutics has announced promising preliminary results from its Phase 1 first-in-human clinical trial of SRSD107, a next-generation siRNA therapeutic under development for the prevention and treatment of thromboembolic disorders.…
Celltrion has announced that Health Canada has approved Omlyclo™, the first and only biosimilar referencing Xolair® (omalizumab) in Canada. Omlyclo™ is now authorized for the treatment of adults and adolescents…
SK pharmteco, a global leader in contract development, manufacturing, and analytical testing services for the pharmaceutical and cell & gene therapy industries, has announced a groundbreaking brand unification initiative. This…
Crown Bioscience, a leading global contract research organization (CRO) based in the United States and a part of JSR Life Sciences and Japan’s JSR Corporation, has been awarded the prestigious…
City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., presented groundbreaking findings at the ASH Annual Conference in San Diego from…
Agilent Technologies today announced the issuance of a Class C Companion Diagnostic (CDx) In Vitro Diagnostic Regulation (IVDR) certification for its PD-L1 IHC 28-8 pharmDx (Code SK005) assay. This diagnostic…
On November 29, the Group of Friends of Traditional Medicine convened in Geneva to explore opportunities for joint action in 2025, fostering collaboration and coordination among WHO Member States. Ambassadors…
Bio-Techne Corporation announced the launch of a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. This innovative assay is designed for research use and aims to detect ESR1…
Silal and Bayer have reinforced their commitment to agricultural innovation in the UAE with the signing of a comprehensive Memorandum of Understanding (MoU) at the World Agri-Tech Innovation Summit in…
Roche presented new and updated findings from its pioneering CD20xCD3 T-cell-engaging bispecific antibody program at the 66th American Society of Hematology (ASH) Annual Meeting, held from December 7-10, 2024. With…
Biogen has appointed Tim Power as Vice President and Head of Investor Relations, effective December 9, 2024. In this role, Mr. Power will report directly to Michael McDonnell, the company’s…